Stay up to date on all things ulcers. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

Benralizumab for Eosinophilic Gastritis

September 9, 2019


This study seeks to assess the effectiveness of repeat doses of benralizumab to reduce eosinophilic inflammation in the gastrointestinal tract of patients with eosinophilic gastritis.


The secondary objectives of the study are to assess a variety of changes in patients before and after treatment with benralizumab. Such changes being assessed include endoscopic score, blood and biopsy eosinophil counts, clinical symptoms, esophageal and gastric changes, amongst others.


Study Information

The goal in 2018 was to enroll 26 participants into the study at Cincinnati Children’s Hospital Medical Center. The study began on March 30th 2018 and is estimated to be completed on March 30th 2021. 

This study is randomized and double-blind, and participants will receive either three doses of the drug or of the placebo. After the initial three month period of receiving either benralizumab or placebo, there will be an optional six month open-label extension period.


Inclusion Criteria

  • Informed Consent: Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.
  • Males and females between the ages of 12-60 years with confirmed diagnosis of EG involving stomach; involvement of eosinophilic inflammation in other gastrointestinal segments will be allowed but not required or sufficient.
  • Histologically active EG at time of screening, with a peak Gastric count of ≥ 30 eos/hpf in at least 5 hpfs.
  • Must be symptomatic (defined as having experienced symptoms within 4 weeks prior to enrollment)
  • Blood eosinophilia (defined as having an absolute eosinophil count > 500 cells per mcL of blood ) at least once during the 6 months prior to enrollment.
  • Must be on baseline anti-EG/EGE therapy as long as there is agreement to not change their dosage unless medically indicated.
  • Clinical symptoms (i.e., abdominal pain, bloating, vomiting, diarrhea) severe enough to impact daily life (e.g., school/work attendance, social activities) ≥ 2 days/week for 3 of the 4 weeks prior to enrollment despite treatment (such as diet, proton pump inhibitors or corticosteroids). See addendum number 1, page 55.
  • Female subjects: Women of childbearing potential (WOCBP) must use an effective form of birth control (confirmed by the Investigator). WOCBP must agree to use effective method of birth control from enrollment throughout the study duration and within 16 weeks after last dose of IP, and have negative serum pregnancy test result on Visit 0.
  • Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of visit -1 without an alternative medical cause. The following age-specific requirements apply:
  • Women <50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range.
  • Women ≥50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
  • All male subjects who are sexually active must agree to use an acceptable method of contraception (condom with or without spermicide, vasectomy) from Visit 0 until 16 weeks after their last dose.


Exclusion Criteria

  • Concurrent H. pylori gastritis or parasitic infection
  • Other gastrointestinal disorders such as Crohn’s disease, inflammatory bowel disease, or Celiac disease
  • Esophageal stricture that prevents the easy passage of a standard endoscope
  • Use of any investigational biologic drug within 6 months prior to screening
  • Hypereosinophilic syndrome, defined by multiple organ involvement (with the exception of atopic disease or EGID) and persistent blood absolute eosinophil count ≥1500/mcL.
  • A diagnosis of celiac disease, inflammatory bowel disease, eosinophilic granulomatosis with polyangiitis (EGPA), drug hypersensitivity or connective tissue rheumatological disorders,
  • History of cancer: Subjects who have had basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the subject is in remission and curative therapy was completed at least 12 months prior to the date informed consent, and assent when applicable was obtained. Subjects who have had other malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to the date informed consent, and assent when applicable, was obtained.
  • A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy.
  • Pregnant or nursing
  • Receipt of any investigational non-biologic within 30 days or 5 half-lives prior to visit 0, whichever is longer.
  • A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.
  • Any other medical illness that precludes study involvement
  • Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to be enrolled.
  • Patients who are currently receiving or have previously received benralizumab or any other type of anti-interleukin therapy (i.e. mepolizumab, reslizumab, lebrikizumab etc.) within the last 6 months or 5 half-lives whichever is longer.
  • History of anaphylaxis to any biologic therapy or vaccine.
  • Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained.



The study is located in Cincinnati, Ohio at the Cincinnati Children’s Hospital Medical Center. For more information contact Tal Cohen on 5135171074 or, or Lauren DiTommaso on 5138035446 or


Sponsors / Collaborators

This study is sponsored by Cincinnati Children’s Hospital Medical Center, Cincinnati and AstraZeneca. The Principal Investigator is Marc E Rothenberg, MD, PhD.

Clinical Trials

View All Clinical Trials

Multi-Center Acute Severe Ulcerative Colitis Cohort Study

Over one-third of patients with ‘acute severe colitis (ASUC)’ will not respond well to the intravenous…

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

T cells are integral to the production and development of ulcerative colitis. GSK2831781 targets these specific T…

Low Sulfur Fecal Transplant for Ulcerative Colitis

It is currently unknown if the microorganisms (microbiota) in patients with ulcerative colitis (UC) is inherently…

Helicobacter Pylori Genome Project

Helicobacter pylori (H. pylori) is a common bacterial infection which can lead to severe stomach problems or…

Changes Associated With H. Pylori and Gastric Carcinogenesis

This is a research study for patients who currently have or previously had an H. pylori infection or who have…

Outcome Measures in Eosinophilic Gastrointestinal Disorders

The aim of this study is to twofold: firstly, to find the best measures to define how well a person with…

Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

NuShield® is a dehydrated, sterile placental allograft (donor tissue…

Send this to a friend